SCHEMBL4962276

SCHEMBL4962276

CCOC(=O)c1cc(C2CC2)c2c(C)c(-c3ccc(CBr)cc3)ccn2c1=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 11/20 0.40
ALDH1A1 P00352 7/20 0.40
HPGD P15428 5/20 0.40
GLA P06280 4/20 0.40
GAA P10253 4/20 0.40
CYP4F2 P78329 1/20 0.39
CYP4A11 Q02928 1/20 0.39
NPSR1 Q6W5P4 1/20 0.36
RXFP1 Q9HBX9 1/20 0.36
FDFT1 P37268 1/20 0.34
HSD17B10 Q99714 4/20 0.34
TP53 P04637 2/20 0.34
NPC1 O15118 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2C19 P33261 1/20 0.34
RAB9A P51151 1/20 0.34
CDK5 Q00535 1/20 0.34
CDK5R1 Q15078 1/20 0.34
PDE3B Q13370 4/20 0.33
PDE3A Q14432 4/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1290164 0.92 KDM4E (0.41) KDM4EALDH1A1HPGDGLAGAA
SCHEMBL1290222 0.90 KDM4E (0.43) KDM4EALDH1A1HPGDGLAGAA
SCHEMBL4966626 0.90 KDM4E (0.40) KDM4EALDH1A1HPGDGLAGAA
SCHEMBL5426746 0.89 KDM4E (0.39) KDM4EALDH1A1HPGDGLAGAA
SCHEMBL5418075 0.89 KDM4E (0.41) KDM4EALDH1A1HPGDGLAGAA
SCHEMBL1290014 0.89 KDM4E (0.43) KDM4EALDH1A1HPGDGLAGAA
SCHEMBL1290318 0.89 KDM4E (0.41) KDM4EALDH1A1HPGDGLAGAA
SCHEMBL5426205 0.88 KDM4E (0.38) KDM4EALDH1A1HPGDGLAGAA
SCHEMBL4967127 0.88 KDM4E (0.40) KDM4EALDH1A1HPGDGLAGAA
SCHEMBL1290170 0.88 ALDH1A1 (0.42) KDM4EALDH1A1HPGDGLAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1437354-B1 4-OXOQUINOLIZINE ANTIMICROBIALS HAVING 2-PYRIDONE SKELETON AS PARTIAL STRUCTURE SATO PHARMA (JP) 2008-08-13 EP disclosed
US-7223773-B2 4-oxoquinolizine antibacterial agent having 2-pyridone skeleton as partial structure SALO PHARMACEUTICAL CO., LTD. (JP) 2007-05-29 US disclosed
US-20040229903-A1 4-Oxoquinolizine antibacterial agent having 2-pyridone skeleton as partial structure SATO PHARMACEUTICAL CO., LTD. (JP) 2004-11-18 US disclosed
EP-1437354-A1 4-OXOQUINOLIZINE ANTIMICROBIALS HAVING 2-PYRIDONE SKELETON AS PARTIAL STRUCTURE Sato Pharmaceutical Co. Ltd. (JP) 2004-07-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040229903-A1 4-Oxoquinolizine antibacterial agent having 2-pyridone skeleton as partial structure SDHA, IL4I1, BLVRB KDM4E 161/4885ALDH1A1 789/4885HPGD 270/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.